Kiniksa CMO exercises options, sells 40K shares

Kiniksa Pharmaceuticals International, plc Chief Medical Officer John F. Paolini exercised options and sold shares of Class A Ordinary Shares.

Rhea-AI Filing Summary

Kiniksa Pharmaceuticals International, plc Chief Medical Officer John F. Paolini exercised options and sold shares of Class A Ordinary Shares. He exercised a fully vested option for 40,000 Share Options at an exercise price of $10.36 per share, acquiring 40,000 Class A Ordinary Shares on March 2, 2026. That same day, he sold a total of 40,000 Class A Ordinary Shares in open-market transactions at weighted average prices ranging from about $43.555 to $46.09, under a Rule 10b5-1 plan executed on November 18, 2025. After these transactions, he directly holds 61,324 Class A Ordinary Shares and 58,424 Share Options.

Insider Trade Summary

Exercise and Sale: 40,000 shares ($1.38M approx. pre-tax spread)

Exercise and Sale 5 txns

Insider Paolini John F.

Role CHIEF MEDICAL OFFICER

Sold 40,000 shs ($1.79M)

Approx. gross sale proceeds $1.79M

Approx. exercise cost $414K

Approx. pre-tax spread $1.38M

Type	Security	Shares	Price	Value
Exercise	Share Option	40,000	$0.00	$0.00
Exercise	Class A Ordinary Share	40,000	$10.36	$414K
Sale	Class A Ordinary Share	12,063	$44.20	$533K
Sale	Class A Ordinary Share	22,223	$44.88	$997K
Sale	Class A Ordinary Share	5,714	$45.92	$262K

Holdings After Transaction: Share Option — 58,424 contracts (Direct); Class A Ordinary Share — 61,324 shares (Direct)

Footnotes (5)

1. F1. This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on November 18, 2025.
2. F2. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $43.555 and $44.55. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
3. F3. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $44.555 and $45.49. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
4. F4. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $45.56 and $46.09. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
5. F5. The option is fully vested and exercisable.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Kiniksa (KNSA) report for John F. Paolini?

Kiniksa reported that Chief Medical Officer John F. Paolini exercised 40,000 Share Options and acquired 40,000 Class A Ordinary Shares, then sold 40,000 Class A Ordinary Shares in open-market transactions on March 2, 2026, pursuant to a pre-arranged Rule 10b5-1 trading plan.

How many Kiniksa (KNSA) shares did the CMO sell and at what prices?

John F. Paolini sold a total of 40,000 Class A Ordinary Shares in multiple broker-executed trades. The weighted average prices for these open-market sales ranged between $43.555 and $46.09 per share, as disclosed across the reported sale price ranges in the filing footnotes.

What options did the Kiniksa (KNSA) CMO exercise in this Form 4 filing?

He exercised a fully vested and exercisable Share Option for 40,000 shares at an exercise price of $10.36 per share. This exercise converted derivative securities into 40,000 Class A Ordinary Shares before the subsequent open-market sales on March 2, 2026.

Was the Kiniksa (KNSA) insider trading under a Rule 10b5-1 plan?

Yes. The filing states the transactions were effected under a Rule 10b5-1 trading plan executed by John F. Paolini on November 18, 2025. Such plans pre-schedule trades, helping insiders diversify holdings while following regulatory requirements and internal trading policies.

How many Kiniksa (KNSA) shares does John F. Paolini hold after these trades?

Following the reported transactions, John F. Paolini directly holds 61,324 Class A Ordinary Shares and 58,424 Share Options. The option grant is described as fully vested and exercisable, indicating he has already satisfied any vesting conditions tied to that award.

What is the overall direction of insider activity in this Kiniksa (KNSA) Form 4?

The Form 4 reflects a mix of activities: an option exercise that increased Paolini’s share ownership, followed by open-market sales totaling 40,000 shares. The transaction summary shows a net-sell position based on the balance of shares acquired versus shares sold.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/04/2026 - 04:40 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Paolini John F.

(Last) (First) (Middle)

C/O KINIKSA PHARMACEUTICALS INT'L, PLC

105 PICCADILLY, SECOND FLOOR

(Street)

LONDON X0 W1J 7NJ

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Kiniksa Pharmaceuticals International, plc [ KNSA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF MEDICAL OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Ordinary Share	03/02/2026		M(1)		40,000	A	$10.36	101,324	D
Class A Ordinary Share	03/02/2026		S(1)		12,063	D	$44.2(2)	89,261	D
Class A Ordinary Share	03/02/2026		S(1)		22,223	D	$44.88(3)	67,038	D
Class A Ordinary Share	03/02/2026		S(1)		5,714	D	$45.92(4)	61,324	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option	$10.36	03/02/2026		M(1)			40,000	(5)	02/29/2028	Class A Ordinary Share	40,000	$0	58,424	D

Explanation of Responses:

1. This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on November 18, 2025.

2. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $43.555 and $44.55. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

3. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $44.555 and $45.49. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

4. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $45.56 and $46.09. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

5. The option is fully vested and exercisable.

	/s/ Douglas Barry, Attorney-in-Fact	03/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.